Cabaletta Bio, a biotechnology company based in Philadelphia, has announced promising early results from its clinical trial of CAR-T therapy aimed at treating a rare autoimmune...
Cabaletta Bio, a Philadelphia-based biotechnology company, has announced promising results from its recent clinical trial involving CAR-T therapy for a rare autoimmune disorder. The findings indicate...
